1841. Activity of Tigecycline and Comparators against Key Bacterial Groups Isolated from Various Infection Sources Encountered in the Asia-Pacific Region: TEST 2011-2015
Session: Poster Abstract Session: Antibacterial Susceptibility Surveillance
Saturday, October 29, 2016
Room: Poster Hall
Posters
  • P14_all sources_Pfizer_ID week_2016_v1 final.pdf (384.3 kB)
  •   Background: The Tigecycline Evaluation Surveillance Trial (TEST) monitors the activity of tigecycline and other antimicrobials against clinically-relevant pathogens collected globally. This study reports on the activity of tigecycline (TGC) in TEST Enterobacteriaceae isolates collected in countries in the Asia-Pacific (APAC) region during the years 2011- 2015. Methods:  Non-duplicate gram-negative and S. aureus isolates from 68 cumulative sites in APAC countries were collected from multiple sources during the years 2011, 2012 and 2015. Organism identification and antibiotic susceptibility (S) testing was performed by the local laboratories. Susceptibility testing was performed using broth microdilution according to CLSI guidelines and categorical interpretation of results was done using CLSI or FDA breakpoint criteria where appropriate. Cefoxitin disk testing was performed for all S. aureus to determine methicillin susceptibility MRSA and MSSA.

    Results: The table provides MIC90 and %S data for TGC and comparators.

     

    A. baumannii (224)

    P. aeruginosa (270)

    Enterobacteriaceae (1201)

    MSSA (200)/MRSA (226)*

    Drug

    %S

    MIC90

    %S

    MIC90

    %S

    MIC90

    %S

    MIC90

    Amikacin

    23.2

    > 64

    87.0

    64

    88.3

    64

    nt**

    nt

    Cefepime

    13.8

    > 32

    65.9

    > 32

    64.0

    > 32

    nt

    nt

    Levofloxacin

    17.0

    > 8

    63.3

    > 8

    65.6

    > 8

    77.5/30.1

    4/32

    Meropenem

    14.4

    > 16

    57.8

    > 16

    90.7

    1

    100/0.0

    0.5/> 16

    Minocycline

    64.7

    8

    na

    > 16

    67.8

    16

    98.0/85.8

    1/8

    Pip- Tazo

    12.5

    > 128

    62.2

    > 128

    77.1

    > 128

    100/0.0

    4/> 16

    Tigecycline

    na***

    2

    na

    16

    96.5

    2

    100/100

    0.25/0.5

    Vancomycin

    nt

    nt

    nt

    nt

    nt

    nt

    100/99.6

    1/1

    *53.1% of the isolates were MRSA **nt; not tested ***na: not applicable for this species  Conclusion: Based on %S and MIC90 data TGC exhibited potent activity against clinically significant species from countries in the APAC region (with the exception of P. aeruginosa).  Only TGC exhibited good in vitro activity against A. baumannii and also exhibited the highest percent susceptibility against Enterobacteriaceae. TGC and vancomycin provided the most potent activity against methicillin-resistant S. aureus isolates. This study demonstrated that in the APAC region TGC continues to provide potent activity against many of the key bacterial groups. However, continued surveillance and monitoring is warranted.

     

    Douglas Biedenbach, MS1, Martha Renteria, MD1, Heidi Leister-Tebbe, BSN2 and Dan Sahm, PhD1, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)Pfizer, Inc., Collegeville, PA

    Disclosures:

    D. Biedenbach, IHMA, Inc.: Independent Contractor , Research support

    M. Renteria, IHMA, Inc.: Independent Contractor , Research support

    H. Leister-Tebbe, Pfizer, Inc.: Employee , Salary

    D. Sahm, IHMA, Inc.: Independent Contractor , Research support

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.